When SRT2014, an agonist of SIRT1, was used to treat moderate to severe psoriasis, it was observed that the expression of known IL-17 and TNF-α responsive genes and that of genes involved in keratinocyte differentiation were significantly downregulated [42]. The gene discussed is TNF; the disease is psoriasis.